Showing 107 results for "diagnosis"

NVP015

NVP015 is a program aimed at developing a systemic treatment for patients with genetic mitochondrial neurological diseases such as Leigh syndrome, and MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes). Developed by the mitochondrial medicine company NeuroVive Pharmaceutical, the NVP015 program’s lead compound has produced positive results…

Mitochondrial Donation IVF

The estimated prevalence of inherited mitochondrial diseases, due to mutations in mitochondrial DNA (mtDNA), is 1 in every 5,000-10,000. Recently, the first U.K. license was granted to researchers at Newcastle University to carry out mitochondrial donation IVF treatment for affected women to give them an option of having children…

Evaluating Respiratory Enzyme Activity in Kidney Biopsies May Help Diagnose Mitochondrial Disease, Study Finds

Determining the respiratory chain enzyme activity in kidney tissue samples could provide useful information for diagnosing mitochondrial dysfunction in children with renal impairment, according to a report in the Journal of Clinical Medicine. Diseases stemming from mitochondrial dysfunction can be difficult to diagnose because of symptoms similar to other…

Stealth’s Elamipretide Granted FDA Orphan Drug Status for Primary Mitochondrial Myopathy

Stealth BioTherapeutics‘ investigational medicine elamipretide, formerly known as Bendavia, has been granted orphan drug status by the U.S. Food and Drug Administration’s (FDA) for the treatment of primary mitochondrial myopathy (PMM). Stealth specializes in the development of drug candidates for mitochondrial disease treatment. The FDA’s Office of Orphan…